Introduction
Pharmaceutical innovation (PI) has contributed to substantial improvements in the health and quality of life of people in modern societies. Indeed, drug innovation has not only allowed for the cure and the prevention of diseases but has also helped to reduce symptoms, increase life expectancy, accelerate recovery time, reduce adverse effects and negative interaction with other drugs, and find new routes of administration that are more comfortable for the patient. 1 such as medication costs, medical visits, hospitalizations and laboratory tests. The latter refers, among other costs, to the value of the care that the patient receives at home, in the form of formal caregiving (i.e. when care is provided by paid professionals) or of informal caregiving (i.e. when care is provided by relatives and friends). Indirect costs are defined as those that include permanent and temporary labour productivity losses caused by the illness, which represent a loss of wealth for society.
The objective of this study is to shed light on the potential that drugs have to generate savings for the healthcare system and for society in general. Throughout the article, we provide different illustrative examples, both in concrete therapeutic areas and in general, that were found through a narrative literature review.
Methods
A narrative literature review was carried out using Medline (PubMed) and Google Scholar. The search included fulltext articles and documents published until September 2017 that analysed or measured the offset effect of drugs. Only documents written in English or Spanish were included. The search terms used included 'offset effect', 'savings', 'costs', 'productivity' and 'drugs'. References of the included studies were also examined. The search was complemented with grey literature and documents of relevant organizations, such as government departments.
Results

Savings in DHC
By improving the patients' health status, the use of new drugs is often translated into a decrease in the utilization of healthcare resources, such as hospitalizations, medical visits, and concomitant medication, leading to financial savings, or releasing resources for other uses within the healthcare system. A growing body of literature has tried to measure the magnitude of this offset effect that is associated with PI, both at the aggregate level and for different concrete pathologies.
Lichtenberg was one of the first authors who quantified the offset effect of drugs at the general level, leading to the notion that PI's economic and social contribution could significantly exceed its costs. In a study published in 2001, the author estimated that if a 15-year-old drug was to be replaced by a 5.5-year-old one, per capita pharmaceutical expenditure in the United States would increase by USD 18 on average, while non-pharmaceutical expenditure would decrease by USD 72, leading to a savings ratio of almost 4 times the cost of the introduction of the newest drug. 4 He later updated his analysis for the years 1997 and 1998 and obtained a savings ratio of 7.2 in the entire population and 8.3 for the population covered by Medicare, basically due to savings in hospitalizations. 5 In another study, Lichtenberg 6 estimated that, even under a most conservative cost methodology, the net cost of new drugs was negative, as they would generate savings in hospitalization and nursing home costs equivalent to 2.4 times the cost of the drugs.
Other authors later found that the magnitude of the aggregate offset effect of new drugs in the United States actually amounted to intermediate values. For example, Civan and Koksal focused on Medicare-and Medicaidcovered population and obtained a net per capita savings ratio of 5.5 when using newer drugs (actually, when the average age of the drug being assessed was reduced in 1 year). However, the authors also found significant heterogeneity among different drug classes. 7 In another study, Santerre (2011) obtained estimations for the United States and six other Organisation for Economic Co-operation and Development (OECD) countries and found larger offset effects in the long run than in the short run. Indeed, according to the author, the marginal effect of commercializing a new medication was equivalent to net per capita savings in healthcare costs of USD 5.9 in the short run and USD 11.4 in the long run. These findings implied aggregated savings at the national level of USD 1800 million and USD 3400 million in the short and long run, respectively. 8 Public organizations like the Congressional Budget Office have also validated the offset effect of PI in the United States. Their study highlighted that, in the case of the Medicare-covered population, a 1% increase in the number of annual prescriptions translated into a 0.2% decrease in annual healthcare costs. 9 Based on this finding and on the volume of prescriptions filled in 2014, Lakdawalla et al. 10 estimated that each additional prescription led to savings of USD 94 in DHC in that same year.
The existence of an offset effect associated with PI has also been confirmed in other countries. For example, in Canada, Crémieux et al. 11 estimated that each additional dollar invested in new drugs yields an average reduction of CAD 4.7 in hospital expenditure and of CAD 1.5 in global healthcare expenditures. In Spain, an increase of 10% in hospital drugs expenditure between 1995 and 2005 led to net per capita savings of EUR 1.1 in total hospital expenditures. 12 
Savings by therapeutic area
Many studies have analysed the economic impact that drugs have in specific therapeutic areas, finding that in those cases, PI also often translates into net savings in costs. In what follows, we summarize some examples found in the literature.
In the oncology area, drugs that were commercialized between 1980 and 1997 in Canada avoided 1.7 million hospitalization days per year, which translated into savings that approximated CAD 4700 million (base year 2012), a significantly higher amount than the annual expenditure in cancer drugs in that country. 13 Likewise, in the United States, a study estimated that cancer treatments launched between 1989 and 2005 avoided 1.55 million hospitalization days in 2013, thereby reducing hospitalization costs by USD 4800 million in that same year. 14 There is also evidence that oncological PI increased healthcare cost savings in Australia. 15 Multiple examples of offset effects have also been found in the cardiovascular area. In OECD countries, pharmaceutical expenditure in cardiovascular illnesses increased by USD 24 per capita between 1995 and 2004, which in turn led to estimated hospitalization savings of USD 89 per capita. 16 A study by the British National Health Service estimated that treating atrial fibrillation patients with anticoagulant therapy was associated with net per capita savings of GBP 412 in the short run and GBP 2408 throughout the patient's lifetime. This same study found additional savings for society of GBP 94 and GBP 1379 in the short and long run, respectively. 17 Likewise, according to a clinical trial conducted in the United States, the use of statins has led to a 27% reduction in other healthcare costs related to illness management, thereby allowing for an 11% reduction in total cardiovascular healthcare costs. 18 Another study found that the use of antihypertensive medication was associated with a benefit-cost ratio of 6:1 in women and of 10:1 in men. 19 Other examples can be found for other illnesses, such as depression, asthma and HIV/AIDS. In the United States, the total net healthcare cost per patient diagnosed with depression was reduced during the 1990s by 18%, mainly due to the decrease in hospitalization costs that was produced by innovations in drug treatment. 20 In Ireland, the use of new monoclonal antibodies in asthmatic patients led to a reduction in exacerbations and allowed for a decrease of 14.5% in net DHC. 21 Finally, studies have demonstrated that while the use of antiretroviral therapy has increased drug expenditure in patients with HIV/ AIDS, it has also decreased other healthcare costs, leading to net savings of 10%. 22 The power of vaccines. Vaccines are one of the most costeffective public health interventions. 23 Their economic value has been studied from different angles, [24] [25] [26] with benefits that can be measured in terms of decreases in morbidity and mortality rates, savings for the healthcare system, gains in labour productivity and positive externalities in both the short and the long run. 27 Traditional vaccines have generated important net savings for the healthcare system and for society. The eradication of smallpox is associated with savings in global costs of over USD 2000 million per year. 23 The net benefit of the polio vaccine in the United States has reached over 6 times its cost. 28 According to another study, each dollar invested in the United States in nine types of children vaccines led to savings of USD 13 in the short run, of which USD 10 corresponded to indirect costs. 25 In the long run, savings in social costs associated with vaccines for children could reach USD 27 for each dollar invested, of which USD 9 would correspond to savings for the healthcare system. 26 It has been estimated that, in low-and middle-income countries, children vaccination programmes generate a return of 44 times their cost (uncertainty range: 27-67) if all social and economic benefits in the long run are taken into account. 24 Influenza vaccines have proved to be an efficient health intervention, especially in high-risk populations, such as the elderly, whose vaccination could avoid up to 39% of influenza-and pneumonia-related hospitalizations, 29 leading in turn to a benefit-cost ratio of over 1 in countries such as England and Wales. 30 A recent systematic review concluded that these vaccines were generally a costeffective option in the European Union. 31 The newest vaccines, such as those to prevent hepatitis and the human papilloma virus, came out of more complex research processes and are therefore more costly than older vaccines. However, they still have proved to be costeffective under a EUR 30,000 per quality-adjusted lifeyear cost-effectiveness threshold. 32 Adherence to treatment as a cost savings driver. A determinant driver for cost savings is the degree of adherence to treatment, as it does not only favour the treatment's success but it also reduces the risk of the patient suffering a relapse. The highest the degree of adherence to treatment, the higher the drug costs associated with it but the lower the total healthcare costs associated with medical visits, hospitalizations and emergency admissions. 33 According to a recent systematic review that was carried out on 14 groups of illnesses, the economic cost of the lack of adherence to treatment ranged between USD 949 and USD 44, 190 per year in the United States. 34 Another study found that each dollar invested in improving adherence to treatment led to net average savings in healthcare costs equivalent to USD 7.1 in diabetes, USD 5.1 in hypercholesterolemia and USD 4 in hypertension. According to this same study, a patient with high adherence level (80%-100%) would save the healthcare system an average of 29% of the costs in hypercholesterolemia, 27% in diabetes, 9% in heart failure and 7% in hypertension, compared to a patient with a medium adherence level (60%-79%) 35 (Figure 1 ). Yet, another study carried out in the United States has estimated that a higher adherence to treatment in the case of chronic illnesses like chronic obstructive pulmonary disease (COPD), diabetes and heart failure would reduce Medicare costs between 29% and 49%. 36 In diabetes, in the context of an integrated disease management programme, a reduction from 8.2% to 7.7% in glycosylated haemoglobin has been associated with a 22% decrease in hospital admissions and a 34% decrease in the patient's average length of stay. 37 Other studies also confirmed that changes in the insulin administration route led to a higher adherence level, reduced hypoglycaemias and generated savings in the average DHC per patient. 38, 39 
Savings in DNHC
As a consequence of illness, many patients have limited autonomy and therefore need personal caregivers, who may either be formal caregivers (professional health workers) or informal caregivers (family or friends). Medication may reduce many limitations patients have when performing daily activities and thereby reduce the amount of personal care they need. Even though literature on the economic impact that drugs may have on caregiving costs is scarce, some studies have been published on this topic.
Regarding informal care, a meta-analysis concluded that medical treatment for dementia reduced both the care burden (with a 0.27 difference in the care burden questionnaire) and the time dedicated to caregiving (a reduction between 25 and 58 minutes per day). 40 In psoriasis, new biologic medications reduced the average burden of care at home from 28 to 10 days in Italy, which in turn reduced missed days at work of caregivers from 8 to 2 days per year. 41 In addition to easing the burden on caregivers, medications may promote efficiency and sustainability within the healthcare system by freeing up resources for other activities. For example, according to a Dutch study that analysed the effect on comprehensive care to patients in a group of 10 PIs that were commercialized between 1995 and 2007, these new drugs represented annual savings that were equivalent to employing 7200 healthcare professionals. 42 
Improvements in labour productivity
Clinical advancements produced by PI may in turn improve the patient's work capacity, which could be directly translated into a lower degree of absenteeism and presenteeism in the labour market. Thus, at the aggregate level, new medicines may contribute to the economic prosperity of a country by increasing its labour supply, the number of hours worked per person and the average productivity per hour, which will result in an improvement in total labour productivity for the whole society.
In Germany, it has been estimated that each new drug has avoided on average around 200 annual years of lost labour productivity due to early retirement and premature mortality. The cumulative gain in this country, in terms of years of work produced between 1988 and 2004 thanks to new medicines, is estimated at around 10% of the labour loss for the year 2004. 43 In some of his studies, Lichtenberg analysed the impact of PI on productivity. He estimated that each additional year of novelty of a drug would lead to a 1% savings in labour productivity losses. Also, according to the author's findings, reducing labour losses in 1 day would require an average cost in medicines of between USD 18 and USD 34. This is at least 4 times lower than the average daily wage in the United States (USD 140), which suggests that this investment in drugs would be convenient for society. 44 In a later study, Lichtenberg estimated the stock value of new drugs in terms of the increase they brought in labour productivity in between 2.3 and 8.1 times the investment they represented. 45 A large amount of the studies in this field focus on specific pathologies. For example, it has been estimated that each dollar invested in medical treatment for depression in the Unites States during the 1990s decade spared USD 0.56 in labour productivity losses. 20 In Italy, among patients with moderate or severe psoriasis, biologic therapies have allowed a reduction of 71.4% in indirect costs associated with the disease. 41 In Germany, new drugs against rheumatoid arthritis have allowed indirect costs to decrease in 8% (from EUR 10,609 per patient in the year 2000 to EUR 9754 per patient in 2012). 46 Adherence to treatment also improves productivity. For instance, adherent workers with diabetes, hypertension, dyslipidaemia, asthma or COPD reduced their absenteeism between 1.7 and 7.1 days per year and had work leaves between 1.1 and 5 days shorter than non-adherent workers. 47 Annual savings in indirect costs associated with adherence to treatments for asthma and COPD approximate USD 1700 per worker in the United States. In Spain, labour productivity losses significantly decrease when asthma/COPD is adequately controlled (from 22% of total costs when not controlled to 2.6% when adequately controlled). 48
Discussions and conclusions
This narrative review of the literature has shed light on the value of PI. New drugs may not only improve population's health but also improve efficiency and sustainability within the healthcare system and society as a whole.
A string of literature indicates the existence of an offset effect of PI and suggests that investment in drugs often releases both healthcare and non-healthcare resources for alternative uses. When this is the case, allocation of resources in drugs procurement can be considered as an investment rather than expenditure. As stated before, numerous examples prove that new drugs can not only be cost-effective but can also generate net savings (Table 1) .
Lichtenberg was one of the first and most proliferous authors in this field. However, myriad other authors have subsequently refined and clarified initial findings. In general, published studies have used two different approaches to analyse offset effects: the aggregate level and the disease level. Both approaches have found significant offset effects of PI, even if a high degree of heterogeneity in the magnitude of the effect has been found across different pathologies and different types of drugs. 7 Most studies focused on the United States, where the offset effect of drugs has helped to design changes in Medicare's coverage policies.
The appropriateness of the methodology used to reach any study's results and conclusions is of the highest importance. There is a string of literature that questions the methods and the evidence used when eliciting published results. These authors sustain that the use of new drugs does not necessarily decrease the demand for other types of healthcare. Thus, at least in the short run, PI would lead to an increase in total healthcare costs. [49] [50] [51] [52] [53] [54] [55] The way in which novelty, savings and costs are measured may have a profound impact on final results. One should also be aware of possible publication bias in one or the other direction.
The review has several limitations. The first one is that it is a narrative review that is aimed at providing a broad overview of the studied domain. It does not differentiate between different types of medicines and populations. It does not always distinguish existing medicines from latest generation products, neither their mode of use. The second limitation is that, it does not judge the methodological quality of the scientific evidence of studies. Finally, a common limitation of many included studies is the inability to establish a causal link between medication adherence and total healthcare costs.
In any case, it seems clear that there is a growing tendency to try to associate investment in PIs with the value they bring to society. Value-based approaches are increasingly being used in decision-making processes in many developed countries that are implementing reforms to promote efficiency and sustainability within their healthcare systems. 56 Value-based prices will depend not only on those health and quality-of-life outcomes attributable to the new drug but also on the savings it may generate, and on society's willingness to pay for the new drug's marginal increase in health compared to that of its comparator. 57 Indeed, countries such as Australia, England and Sweden take into account evidence related to drugs' offset effect in order to decide whether to allow a price premium or not when it comes to a new drug for a particular illness, including evidence on potential savings that may arise in non-healthcare services. 49, 58 Nevertheless, in many countries, the possibility that the consumption of new drugs may generate nonpharmaceutical healthcare costs or savings either in the very short run or in the medium long run seems to be a missing consideration in deliberations regarding drug price control policy deliberation. Given that the offset effect has important healthcare policy implications, gathering robust evidence is critical. Decision-makers need more rigorous longitudinal studies to assess whether different drug groups or specific drugs improve health results and decrease global costs. Evidence must consider all possible cost spectrum, including not only DHC but also possible impacts on caregiving burden and labour productivity. Time is also an important factor, that is, addressing whether the use of a given medication precedes, is contemporaneous with, or follows non-drug healthcare costs in a given year.
In conclusion, in order to assess the real social value of new drugs, researchers should consider not only their cost but also their potential offset effect in terms of savings to the healthcare system and to society as a whole. Further subgroup analyses are needed to endorse current published results. However, there is enough evidence that sustains the notion that PI often contributes to society not only in terms of clinical benefits but also in terms of efficiency and sustainability.
